DCTD Cancer Imaging

DCTD癌症成像

• 批准号: 8008856
• 负责人: LARRY ARTHUR
• 金额: $ 300万
• 依托单位: LEIDOS BIOMEDICAL RESEARCH, INC.
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-09-26 至 2018-09-25
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8008856
• 关键词: Amendment; American College of Radiology Imaging Network; Annual Reports; Authorization documentation; Back; Biological; Blood; Brain Neoplasms; Cetuximab; Clinical; Clinical Data; Clinical Research; Clinical Trials; Communities; Complement 3d; Computer Assisted; Contracts; Contrast Media; Cyclotrons; Databases; Decision Making; Deoxycytidine; Development; Diagnosis; Diagnostic; Educational workshop; Emission-Computed Tomography; Estrogen Receptors; Ferumoxtran-10; Goals; Growth; Half-Life; Hypoxia; Image; Informatics; Internet; Investigation; Investigational Drugs; Joints; Letters; Magnetic Resonance Imaging; Malignant Neoplasms; Malignant neoplasm of cervix uteri; Malignant neoplasm of lung; Manufacturer Name; Medical; Medical Imaging; Metastatic Neoplasm to the Bone; Metastatic Prostate Cancer; Mission; Modality; Monitor; Pamphlets; Patients; Pharmaceutical Preparations; Pharmacologic Substance; Phase; Photons; Positioning Attribute; Preparation; Procedures; Radiopharmaceuticals; Regulatory Affairs; Reporting; Research; Research Personnel; Scientific Societies; Serious Adverse Event; Site; Staging; Stratification; Systems Biology; Testing; Tetrahydrouridine; Therapeutic; Thymidine; Tracer; Translations; United States National Institutes of Health; Work; Writing; bench to bedside; cancer Biomedical Informatics Grid; cancer imaging; cancer therapy; data management; drug development; ferumoxytol; image archival system; imaging informatics; infrastructure development; innovation; interest; lymph nodes; malignant breast neoplasm; meetings; molecular imaging; outreach; preclinical study; programs; text searching; therapeutic development; tomography; tool; treatment response; virtual

The Cancer Imaging Program (CIP) supports projects in regulatory affairs, medical imaging agent availability, and imaging informatics under the overall mission of supporting discovery and development of cancer treatment modalities utilizing imaging platforms. The regulatory support that CMRP provides to the Cancer Imaging Program has enabled wider availability of investigational agents for exploratory clinical trials -- by contract, in the research community, and within the Joint Early Phase Therapeutics Development Program (JDC) and the Imaging Drug Group (IDG). The program supports INDs for agents being evaluated in brain tumors, metastatic prostate cancer, cervical cancer, metastatic breast cancer and lung cancer. These medical imaging drugs include Position Emission Tomography (PET), single Photon Emission Computed Tomography (SPECT), and Magnetic Resonance Imaging (MR) specific contrast agents. Additionally, the Regulatory Affairs Director collaborates with other programs within NCI, with other groups within NIH at the Clinical Center and Frederick, and with scientific societies and FDA to support the CIP program goals of wider use of medical imaging in diagnosis, stratification of patients to treatments, response to therapy monitoring, therapeutic drug development and medical decision making. These activities include web, meeting, and workshop outreach; advising interested parties on the requirements of clinical research with IND agents, providing letters of authorization to CIP INDs to independent researchers and pharmaceutical companies that wish to file their own INDs for research, encouraging the small radiopharmaceutical manufacturers to file the needed Drug Master Files to permit wider use of short half-life agents that have no IP associated with them. An important aspect of the program is its application to systems biology and investigation of the basic biological mechanisms of cancer genesis and growth. The effort is translations, with bench to bedside and back a key aspect of the program. The IT management support is a major contributor to initiatives across NCI in support of its imaging informatics plan. An IT manager collaborates with multiple NCI-wide committees and oversees the major initiatives in imaging informatics. This work has proven important in the NCI's development of an infrastructure that supports imaging informatics and is aimed at higher-level compatibility with CBIIT's caBIG (Cancer Biomedical Informatics Grid) and other NIH Roadmap Initiatives. The National Cancer Imaging Archive (NCIA) contains databases of medical images that can now be used by outside entities to develop and test computer aided diagnostic tools for lung cancer, virtual colonography, and brain tumors.

癌症成像计划（CIP）支持监管事务，医学成像剂的可用性和成像信息学的项目，该项目是利用成像平台的发现和开发癌症治疗方式的整体使命。 CMRP为癌症成像计划提供的监管支持使研究剂可用于探索性临床试验的更广泛的可用性 - 通过合同，研究界以及联合早期阶段治疗学发展计划（JDC）和成像药物组（IDG）。该计划支持在脑肿瘤，转移性前列腺癌，宫颈癌，转移性乳腺癌和肺癌中评估药物的IND。这些医学成像药物包括位置发射断层扫描（PET），单光子发射计算机断层扫描（SPECT）和磁共振成像（MR）特定对比剂。 此外，监管事务主任与NCI内的其他计划，NIH内的其他群体在临床中心和弗雷德里克（Frederick）以及科学社会和FDA合作，以支持CIP计划在诊断中更广泛使用医学成像，对患者进行治疗分层，治疗，治疗药物监测，治疗药物药物开发和医疗决策的反应。这些活动包括网络，会议和研讨会外展；向感兴趣的方向与IND代理商的临床研究要求提供建议，向希望提交自己的IND进行研究的独立研究人员和制药公司提供授权书，以鼓励您提出自己的IND研究，从而鼓励小型的放射性药物主机提交所需的药物主文件，以允许更广泛地使用与与之相关的短期寿命。 该计划的一个重要方面是将其应用于系统生物学和研究癌症起源和生长的基本生物学机制的研究。努力是翻译，台式为床边，并返回程序的关键方面。 IT管​​理支持是NCI倡议的主要贡献者，以支持其成像信息学计划。 IT经理与多个NCI范围的委员会合作，并监督成像信息学的主要举措。事实证明，这项工作在NCI的发展基础设施中很重要，该基础设施支持成像信息学，旨在与CBIIT的Cabig（癌症生物医学信息学网格）和其他NIH路线图计划的更高层次兼容。国家癌症成像档案库（NCIA）包含医学图像的数据库，现在外部实体可以使用这些数据库来开发和测试计算机辅助的肺癌，虚拟造影术和脑肿瘤的诊断工具。